100Plus is a fast-growing remote patient monitoring (RPM) platform. The company’s suite of remote patient monitoring technologies includes Blood Pressure Cuff, Digital Weight Scale, Emergency Watch, and Blood Glucose Monitor. Ava is 100Plus’ AI powered healthcare assistant that is specifically intended for senior patients who may not be tech savvy or as open to new technologies.
Ava healthcare assistant reviews a patient’s demographics, medical history, and biotelemetry to personalize how it communicates to each individual person, reports MedGadget. It uses machine learning to enable patients to interact, ask questions, and receive tailored responses, while following strict security and adherence to patient privacy regulations. The company reports that Ava has already facilitated 660,000 health alerts and three million device readings.
“When we developed Ava, we considered the fact that seniors are not only less tech savvy, but also less trusting of new technologies. Ava is remarkable because it leverages machine learning to personify the staff at a physician practice, providing a truly personal touchpoint. This is important because we know that these patients are more responsive to direct physician advice and the technology comes across as a member of the practice. Ava also works through SMS and doesn’t require an app or internet service,” Ryan Howard, CEO of 100Plus told MedGadget’s Conn Hastings in an interview.
Today, 80 percent of U.S. seniors over the age of 65 have at least one chronic disease which accounts for 95 percent of Medicare spending.
In March 2021, 100Plus raised $25M in seed investment, led by Henry Kravis, George Roberts, and other super angel investors. 100Plus is the only remote patient monitoring product to utilize artificial intelligence (AI) and offer an end-to-end solution, including patient outreach, device setup, patient engagement and automated billing. The company has ramped revenue to $5M in annual recurring revenue since its launch in January of 2020 and is poised to continue to build upon this growth.